For research and educational purposes only. Not intended for human consumption.
PE-22-28
Limited Research- •TREK-1 channel antagonism mechanism confirmed
- •Rapid neurogenesis effects in preclinical models
- •CREB/BDNF pathway activation studies
TREK-1 Channel Blocker | Rapid Antidepressant Research
Overview
What is PE-22-28?
PE-22-28, also known as Mini-Spadin, is a synthetic heptapeptide derived from positions 22-28 of the parent peptide Spadin. It is a potent and selective antagonist of TREK-1 potassium channels with an IC50 of 0.12 nM - approximately 300-500 fold greater affinity than full-length Spadin. Preclinical research shows rapid antidepressant effects within 4 days, accompanied by neurogenesis and synaptogenesis.
Key Benefits
Rapid antidepressant-like effects (4 days in preclinical models), hippocampal neurogenesis, synaptogenesis, CREB activation, enhanced serotonergic neurotransmission, ~23 hour duration of action.
Mechanism of Action
PE-22-28 selectively blocks TREK-1 potassium channels. TREK-1 inhibition increases neuronal excitability in the dorsal raphe nucleus, enhancing serotonin firing rate. This triggers CREB phosphorylation, BDNF expression, and hippocampal neurogenesis.
Molecular Information
Pharmacokinetics
Research Indications
Depression Research
Preclinical studies show rapid antidepressant effects in forced swim test, tail suspension test, and learned helplessness models. Acts faster than SSRIs with 4-day efficacy window.
Neurogenesis Enhancement
PE-22-28 nearly doubles hippocampal BrdU-positive (newborn) cells after 4-day treatment.
Research Protocols
Disclaimer: PE-22-28 is a research compound with NO human clinical trials. All dosing is extrapolated from animal studies. Use with extreme caution.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Preclinical Antidepressant (Mouse) | 3-4 mcg/kg | Once daily | Intraperitoneal |
| Research Protocol (Human Equivalent) | 50-100mcg | Once daily | Subcutaneous |
| Conservative Research Protocol | 100-200mcg | Once daily | Subcutaneous |
Timing: PE-22-28 has ~23 hour duration of action, supporting once-daily administration. Morning dosing is common.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Remove vial from refrigerator and allow to reach room temperature
Clean rubber stopper with alcohol swab
Determine reconstitution volume (e.g., 2mL BAC water for 10mg = 5mg/mL)
Inject BAC water slowly down inside wall of vial
Gently swirl until completely dissolved - do not shake
Solution should be clear and colorless
Label with reconstitution date and concentration
Store at 2-8°C, use within 4-6 weeks
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
White lyophilized powder
Should appear as white to off-white fluffy cake.
Clear reconstituted solution
Must be completely clear with no particles.
COA available
Third-party testing showing >98% purity.
Research compound status
Not FDA-approved. Available only as research chemical.
Cloudy or discolored
Any turbidity or color indicates degradation.
What to Expect
- •Day 1-4: Preclinical data suggests measurable effects within 4 days
- •Week 1-2: Neuroplasticity processes underway
- •Week 2-4: If effective, mood and cognitive improvements may become noticeable
- •Week 4-8: Sustained use allows full neurogenic effects
- •Note: No human clinical trials - all timing based on animal extrapolation
Side Effects & Safety
Side Effects
- •NOT FDA-approved - research compound only with no human clinical trials
- •All safety data is from preclinical (animal) studies
- •Preclinical studies show no effects on cardiac hERG channels - suggests cardiac safety
- •Theoretical serotonin syndrome risk if combined with MAOIs or high-dose SSRIs
- •Long-term safety in humans completely unknown
- •Not recommended during pregnancy or breastfeeding
When to Stop
- •Signs of serotonin syndrome
- •Significant mood changes
- •Any unexpected symptoms
- •As directed by healthcare provider
References
3 StudiesTREK-1 Antagonism and Antidepressant Effects
Mouse | 3-4 mcg/kg IP | 4 days | Rapid antidepressant effects
PE-22-28 showed antidepressant effects in multiple behavioral tests within 4 days - significantly faster than SSRIs.
Neurogenesis and Synaptogenesis
Mouse | Chronic administration | Doubled hippocampal neurogenesis
PE-22-28 nearly doubled BrdU-positive cells and increased PSD-95 expression after 4-day treatment.
TREK-1 Selectivity Profile
In vitro | Multiple K+ channels | No effects on other K+ channels
PE-22-28 showed no effects on TREK-2, TRAAK, TASK-1, TRESK, or cardiac hERG channels.
Quick Start Guide
Research Disclaimer
PE-22-28 is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving PE-22-28 must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of PE-22-28 for any purpose. Consult qualified professionals for any research applications.